|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Inhibiting the induced brain CYP2D reversed the change in oxycodone levels (1.2-fold; P > 0.1) and analgesia (1.1-fold; P > 0.3).
|
29266563 |
2019 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we would recommend CYP2D6 genotyping to anticipate the needs for analgesia, which will help to adjust opioid dose and maximize clinical efficacy while reducing side effects.
|
29546421 |
2019 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tramadol labeling indicates cytochrome P450 (CYP) isozyme 2D6 ultrarapid metabolizer can produce dangerous (+)-M1 levels, and CYP2D6 poor metabolizers insufficient (+)-M1 for analgesia.
|
31005596 |
2019 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2D6 and CYP3A genotypes did not affect analgesic concentration or duration of analgesia.
|
28643329 |
2018 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients.
|
25825958 |
2015 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate whether the different CYP2D6*10 genotypes have an effect on the postoperative tramadol analgesia in the Chinese population after elective nephrectomy.
|
25948472 |
2015 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Influence of CYP2D6 activity on pre-emptive analgesia by the N-methyl-D-aspartate antagonist dextromethorphan in a randomized controlled trial of acute pain.
|
23340533 |
2013 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
These cases demonstrate that analgesia with codeine or other opioids that use the CYP2D6 pathway after adenotonsillectomy may not be safe in young children with obstructive sleep apnea syndrome.
|
22492761 |
2012 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim was to study the relationship between CYP2D6 genotype and codeine analgesia among women recovering from c-section.
|
21743374 |
2011 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate whether CYP2D6 poor metabolizers (PMs) yield the same analgesia post-operatively from intravenous oxycodone as extensive metabolizers (EMs).
|
19719813 |
2010 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
The case we present, as well as the literature we review, demonstrates the clinical utility of CYP2D6 genotyping in patients with adverse effects from analgesia therapy.
|
17986163 |
2007 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Whereas it is known that individuals lacking CYP2D6 activity (poor metabolizers, PM) suffer from poor analgesia from codeine, ultra-fast metabolizers (UM) due to the CYP2D6 gene duplication may experience exaggerated and even potentially dangerous opioidergic effects and no systematical study has been performed so far on this question.
|
16819548 |
2007 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study indicates that the CYP2D6*10 allele has significant impact on analgesia with tramadol in a Chinese population.
|
16960721 |
2006 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is unclear whether these other pro-drugs may be as completely dependent on CYP2D6 for their analgesia as codeine.
|
16631290 |
2006 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Therefore, CYP2D6 genotype has an impact on analgesia with tramadol.
|
14499440 |
2003 |